A study of antibody-producing B cells from patients who recovered from COVID-19 reveals a new cross-reactive antibody and what makes some B cells more effective at neutralizing the virus.
A team studying rare kidney diseases pivoted to lung injury and identified an FDA-approved drug that’s now being tested as a potential COVID-19 treatment.